129 related articles for article (PubMed ID: 38360825)
1. Outcomes of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system.
Zhang H; Zheng X; Guo W; Xia Y; Zhang R; Zhai W; Chen X; Ma Q; Yang D; Wei J; Pang A; He Y; Feng S; Wang J; Han M; Jiang E
Exp Hematol Oncol; 2024 Feb; 13(1):16. PubMed ID: 38360825
[TBL] [Abstract][Full Text] [Related]
2. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
[TBL] [Abstract][Full Text] [Related]
3. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Hansen DK; Kim J; Thompson Z; Hussaini M; Nishihori T; Ahmad A; Elmariah H; Faramand R; Mishra A; Davila ML; Khimani F; Lazaryan A; Sallman D; Liu H; Perez LE; Fernandez H; Nieder ML; Lancet JE; Pidala JA; Anasetti C; Bejanyan N
Transplant Cell Ther; 2021 Mar; 27(3):256.e1-256.e7. PubMed ID: 33781526
[TBL] [Abstract][Full Text] [Related]
4. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.
Oran B; Jimenez AM; De Lima M; Popat UR; Bassett R; Andersson B; Borthakur G; Bashir Q; Chen J; Ciurea SO; Jabbour E; Cortes J; Kebriaei P; Khouri IF; Qazilbash MH; Ravandi F; Rondon G; Lu X; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1405-1412. PubMed ID: 25840338
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for post-transplant relapse and survival in younger adult patients with t(8;21)(q22;q22) acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: A multicenter retrospective study.
Zhou W; Chen G; Gong D; Gao Y; Yu L
Front Oncol; 2023; 13():1138853. PubMed ID: 36845681
[TBL] [Abstract][Full Text] [Related]
6. ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation.
Jentzsch M; Grimm J; Bill M; Brauer D; Backhaus D; Goldmann K; Schulz J; Niederwieser D; Platzbecker U; Schwind S
Bone Marrow Transplant; 2021 Apr; 56(4):936-945. PubMed ID: 33208914
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation.
Jentzsch M; Bischof L; Ussmann J; Backhaus D; Brauer D; Metzeler KH; Merz M; Vucinic V; Franke GN; Herling M; Platzbecker U; Schwind S
Blood Cancer J; 2022 Dec; 12(12):170. PubMed ID: 36529759
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic Hematopoietic Stem Cell Transplantation Improved Survival for Adult Core Binding Factor Acute Myelogenous Leukemia Patients with Intermediate- and Adverse-Risk Genetics in the 2017 European LeukemiaNet.
Wang T; Chen S; Chen J; Liu T; Zhang T; Qiu H; Sun A; Chen S; Wu D; Xu Y
Transplant Cell Ther; 2021 Feb; 27(2):173.e1-173.e9. PubMed ID: 33830030
[TBL] [Abstract][Full Text] [Related]
9. Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study.
Meur GL; Plesa A; Larcher MV; Fossard G; Barraco F; Loron S; Balsat M; Ducastelle-Leprêtre S; Gilis L; Thomas X; Ghesquières H; Tigaud I; Hayette S; Huet S; Sujobert P; Renault M; Thérèse RM; Michallet M; Labussière-Wallet H; Heiblig M
Transplant Cell Ther; 2023 Jan; 29(1):38.e1-38.e9. PubMed ID: 36108977
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation.
Grimm J; Jentzsch M; Bill M; Goldmann K; Schulz J; Niederwieser D; Platzbecker U; Schwind S
Blood Adv; 2020 Aug; 4(16):3864-3874. PubMed ID: 32810221
[TBL] [Abstract][Full Text] [Related]
11. Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk Stratification.
Kim TY; Park S; Kwag D; Lee JH; Lee J; Min GJ; Park SS; Jeon YW; Shin SH; Yahng SA; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Lee JW; Kim HJ
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804971
[TBL] [Abstract][Full Text] [Related]
12. Wilms' tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.
Deng DX; Wen JJ; Cheng YF; Zhang XH; Xu LP; Wang Y; Yan CH; Chen YH; Chen H; Han W; Wang FR; Wang JZ; Qin YZ; Liu KY; Huang XJ; Zhao XS; Mo XD
BMC Cancer; 2021 Mar; 21(1):292. PubMed ID: 33740924
[TBL] [Abstract][Full Text] [Related]
13. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
14. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.
Lo MY; Tsai XC; Lin CC; Tien FM; Kuo YY; Lee WH; Peng YL; Liu MC; Tseng MH; Hsu CA; Chen JC; Lin LI; Sun HI; Chuang YK; Ko BS; Tang JL; Yao M; Chou WC; Hou HA; Tien HF
Am J Hematol; 2023 May; 98(5):760-769. PubMed ID: 36861732
[TBL] [Abstract][Full Text] [Related]
15. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
16. Pretransplantation minimal residual disease monitoring by multiparameter flow cytometry predicts outcomes of AML patients receiving allogeneic hematopoietic stem cell transplantation.
Zhang Y; Wang P; Cassady K; Zou Z; Li Y; Deng X; Yang W; Peng X; Zhang X; Feng Y
Transpl Immunol; 2022 Jun; 72():101596. PubMed ID: 35390479
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic stem cell transplantation could improve the survival of acute myeloid leukemia patients with ASXL1 mutations.
Zhou L; An J; Hou C; Ding Z; Qiu H; Tang X; Sun A; Chen S; Xu Y; Liu T; Wu D
Hematology; 2021 Dec; 26(1):340-347. PubMed ID: 33840380
[No Abstract] [Full Text] [Related]
19. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia.
Fenwarth L; Thomas X; de Botton S; Duployez N; Bourhis JH; Lesieur A; Fortin G; Meslin PA; Yakoub-Agha I; Sujobert P; Dumas PY; Récher C; Lebon D; Berthon C; Michallet M; Pigneux A; Nguyen S; Chantepie S; Vey N; Raffoux E; Celli-Lebras K; Gardin C; Lambert J; Malfuson JV; Caillot D; Maury S; Ducourneau B; Turlure P; Lemasle E; Pautas C; Chevret S; Terré C; Boissel N; Socié G; Dombret H; Preudhomme C; Itzykson R
Blood; 2021 Jan; 137(4):524-532. PubMed ID: 32871585
[TBL] [Abstract][Full Text] [Related]
20. FLT3-ITD Allelic Ratio and NPM1 Mutation Do Not Impact Outcomes in Acute Myeloid Leukemia Patients with FLT3-ITD after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Propensity Score- Matching Study.
Zhou C; Zheng F; Xu L; Zhang X; Chang Y; Mo X; Sun Y; Huang X; Wang Y
Transplant Cell Ther; 2023 Jul; 29(7):456.e1-456.e11. PubMed ID: 37028555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
